Palvella Therapeutics (NASDAQ:PVLA) Upgraded to “Strong-Buy” at Jones Trading

Jones Trading upgraded shares of Palvella Therapeutics (NASDAQ:PVLA) to a strong-buy rating in a report issued on Monday,Zacks.com reports.

A number of other equities analysts have also weighed in on PVLA. Scotiabank assumed coverage on shares of Palvella Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price for the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, February 26th. TD Cowen began coverage on Palvella Therapeutics in a research report on Wednesday, February 5th. They set a “buy” rating and a $44.00 target price on the stock. Cantor Fitzgerald assumed coverage on Palvella Therapeutics in a research report on Wednesday, December 18th. They issued an “overweight” rating for the company. Finally, HC Wainwright reissued a “buy” rating and set a $38.00 price objective on shares of Palvella Therapeutics in a report on Tuesday, February 11th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $43.50.

Palvella Therapeutics Stock Up 2.4 %

NASDAQ:PVLA opened at $27.93 on Monday. The stock has a market capitalization of $313.40 million, a P/E ratio of -2.31 and a beta of 0.54. The stock has a fifty day moving average price of $19.66. Palvella Therapeutics has a 1 year low of $6.20 and a 1 year high of $29.27.

Institutional Investors Weigh In On Palvella Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC purchased a new stake in shares of Palvella Therapeutics in the 4th quarter valued at about $125,000. Toronto Dominion Bank purchased a new stake in Palvella Therapeutics in the fourth quarter valued at approximately $159,000. Geode Capital Management LLC bought a new stake in Palvella Therapeutics during the fourth quarter valued at approximately $171,000. Cresset Asset Management LLC purchased a new position in Palvella Therapeutics in the 4th quarter worth approximately $251,000. Finally, Renaissance Technologies LLC bought a new position in shares of Palvella Therapeutics in the 4th quarter worth $256,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.